Epidemiology of osteoporosis in Colombia

Ardila, Enrique

doi:10.1016/s8756-3282(01)00518-x

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4 A report by the National Institute of Health of Colombia showed a higher overall prevalence of osteoporosis in Colombia compared with other locations for all age groups and an abrupt increase in the number of Colombian women with osteoporosis during the fifth and sixth decade of life. 5 Teriparatide (recombinant human parathyroid hormone) is a bone-forming medication delivered by subcutaneous injection that preferentially stimulates osteoblasts to produce new bone tissue, thereby increasing bone mass and strength. Once-daily administration of teriparatide over the course of up to 24 months of treatment in postmenopausal women and men with osteoporosis reduces vertebral and non-vertebral fractures [6][7][8][9] but is often restricted to more advanced disease.…”

Section: Introductionmentioning

confidence: 99%

<p>Patient Preferences for Biologic and Biosimilar Osteoporosis Treatments in Colombia</p>

Graham-Clarke¹,

Hauber²,

Boeri³

et al. 2020

PPA

View full text Add to dashboard Cite

Purpose: Teriparatide is used to treat patients with established osteoporosis but is often reserved for patients who have inadequate response to antiresorptive therapy. Biosimilar teriparatide, which is believed to have efficacy and safety similar to the originator product, is now available in Colombia. However, little is known about patients' preferences for originator biologic and biosimilar treatments. Our objective was to quantify the relative importance that patients in Colombia place on features of injectable osteoporosis treatments including whether the treatment is an originator biologic or a biosimilar. Patients and Methods: We used a discrete choice experiment (DCE) to elicit preferences of patients with osteoporosis treatment devices in Colombia. The survey was completed by 200 respondents at high risk of fracture, with or without teriparatide experience. Each treatment alternative within the DCE was characterized by five attributes: type of medicine (originator biologic, biosimilar), needle length, angle of injection, how to measure the medicine dose, and how long the medicine can be left unrefrigerated. A random parameters logit regression was used to estimate preferences and conditional relative attribute importance, while controlling for preference heterogeneity. Results: A total of 200 patients (mean age = 58.3 years) completed the survey. Most were female (84.5%) and married (54.5%); 50.5% had secondary education or less, 21% had current teriparatide exposure. The attribute with the highest conditional relative importance estimate (standard error) was biologic versus biosimilar (10 [1.11]), followed by needle length (8.06 [1.11]), dose measurement (6.38 [0.87]), refrigeration (3.81 [1.18]), and angle of injection (1.30 [0.66]). Unobserved preference heterogeneity was present and controlled for in the analyses. Conclusion: Despite the availability of biosimilar teriparatide in Colombia, patients expressed a strong preference for an originator biologic osteoporosis medicine over a biosimilar osteoporosis medicine, when the efficacy, safety, and cost of the two options were assumed to be the same.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Patient Preferences for Biologic and Biosimilar Osteoporosis Treatments in Colombia</p>

Graham-Clarke¹,

Hauber²,

Boeri³

et al. 2020

PPA

View full text Add to dashboard Cite

show abstract

“…En Colombia se han reportado estudios que muestran prevalencias de osteopenia de entre 49,7% y 47,5% en mujeres mayores de 50 años, diagnosticadas mediante densitometría ósea en columna vertebral y fémur proximal Universidad de Manizales -Facultad de Ciencias de la Salud respectivamente, al tiempo que la prevalencia de osteoporosis franca alcanzó guarismos de 15,7% y 11,4%; se registra además una tendencia de un incremento abrupto de osteopenia y osteoporosis en mujeres colombianas entre la quinta y sexta décadas de vida, superior al de otras regiones estudiadas 4 .…”

Section: Introductionunclassified

Masa osea reducida e hipovitaminosis D en mujeres posmenopausicas: estudio exploratorio en Villavicencio, Colombia. 2012-2013

Rosero¹,

Rojas

Dı́az

2015

archmed

View full text Add to dashboard Cite

Antecedentes: Los niveles de vitamina D en humanos han sido ampliamente estudiados alrededor el mundo, sin embargo la mayoría de estudios se han realizado en áreas geográficas donde hay estaciones climáticas y una gran variación en la exposición solar de sus pobladores. La hipovitaminosis D, se asocia a baja masa ósea y riesgo aumentado de caídas y fracturas en mujeres postmenopáusicas, la prevalencia de déficit de vitamina D varía entre 11 y 70% en diferentes poblaciones estudiadas. Objetivo. Determinar la prevalencia de hipovitaminosis D, asociado a baja masa ósea en la ciudad de Villavicencio entre enero de 2012 y diciembre de 2013. Materiales y Métodos. Se adelantó un estudio descriptivo de corte transversal; de manera secuencial no probabilística se realizó densitometría ósea (DXA) y se midieron las concentraciones séricas de Calcio, Vitamina D y Paratohormona a una muestra de 106 mujeres posmenopáusicas. Resultados. Media de edad 65,9 años (SD=10,4). La media de niveles de Vitamina D en mujeres mayores de 60 años fue de 30,23% (SD: 11,6). Tan solo el 39,6% de las pacientes tenían niveles suficientes de vitamina D, encontrando deficiencia en el 60,37%. Se encuentra una mayor proporción de osteoporosis en las mujeres que presentan deficiencia de Vitamina D (77,3%), cuando se compara con el grupo que se presenta con insuficiencia (64,3%) y con las que tienen concentraciones normales de vitamina D (61,9%). Conclusión. El déficit de vitamina D es altamente prevalente en mujeres con baja masa ósea en la ciudad de Villavicencio, se sugiere la necesidad de intervenciones preventivas en las mujeres, al llegar a la perimenopausia, que permitan incrementar en el aporte de Vitamina D.

show abstract

Determining osteoporosis risk in older Colono adults from rural Amazonian Ecuador using calcaneal ultrasonometry

Madimenos

Liebert

Cepon-Robins

et al. 2014

American J Hum Biol

View full text Add to dashboard Cite

Objective Low bone density and osteoporosis prevalence, while well-documented in wealthy nations, are poorly studied in rural, non-clinical contexts in economically-developing regions such as Latin America. This study contributes preliminary osteoporosis risk data for a rural Colono (mestizo) population from Amazonian Ecuador. Methods Anthropometrics were collected for 119 adult participants (74 females, 45 males [50–90 years old]). Heel bone density and T-scores were recorded using calcaneal ultrasonometry Results Approximately 33.6% of the participants had low bone density and were at high-risk for osteoporosis. Four times as many females as males were considered high-risk. Consistent with epidemiological literature, advancing age was significantly associated with lower bone density values (p=0.001). Conclusions Low bone density and osteoporosis prevalence are expected to increase in this and other economically-transitioning populations, yet infrastructure to monitor this changing epidemiological landscape is almost non-existent. Human biologists are uniquely positioned to contribute data from remote populations, a critical step towards initiating increased resource allocation for diagnosis and prevention.

show abstract

Epidemiology of osteoporosis in Colombia

Cited by 5 publications

References 0 publications

<p>Patient Preferences for Biologic and Biosimilar Osteoporosis Treatments in Colombia</p>

<p>Patient Preferences for Biologic and Biosimilar Osteoporosis Treatments in Colombia</p>

Masa osea reducida e hipovitaminosis D en mujeres posmenopausicas: estudio exploratorio en Villavicencio, Colombia. 2012-2013

Determining osteoporosis risk in older Colono adults from rural Amazonian Ecuador using calcaneal ultrasonometry

Contact Info

Product

Resources

About